• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Takeda Pharmaceutical Company Limited

    4/1/25 6:07:09 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TAK alert in real time by email
    6-K 1 form6k_040125.htm 6-K Document



    FORM 6-K


    U.S. SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    Report of Foreign Private Issuer
    Pursuant to Rule 13a-16 or 15d-16 of
    the Securities Exchange Act of 1934
    For the month of April 2025

     Commission File Number: 001-38757
    TAKEDA PHARMACEUTICAL COMPANY LIMITED
    (Translation of registrant’s name into English)

    1-1, Nihonbashi-Honcho 2-Chome
    Chuo-ku, Tokyo 103-8668
    Japan
    (Address of principal executive offices)


    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
    Form 20-F  ☒            Form 40-F  ☐
    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐
    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐





    Information furnished on this form:
    EXHIBIT
    Exhibit
    Number
    1
    Takeda Provides Update on Status of Acquisition of Own Shares




    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
    TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Date: April 1, 2025By:/s/ Norimasa Takeda
    Norimasa Takeda
    Chief Accounting Officer and Corporate Controller




    Statement

    Takeda Provides Update on Status of Acquisition of Own Shares
    (Pursuant to the provision of its Articles of Incorporation in accordance with
    Article 459, paragraph 1 of the Companies Act of Japan)

    OSAKA, Japan, April 1, 2025 – Takeda (TSE:4502/NYSE:TAK) today provided an update on the status of acquisition of its own shares which has been carried out pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act of Japan, as detailed below.
    1. Class of shares acquired:
     Shares of common stock
    2. Number of shares acquired:
    4,513,800 shares
    3. Acquisition cost of shares acquired:
    JPY 20,144,679,100
    4. Period of acquisition:
    From March 1, 2025 to March 31, 2025
    (execution base)
    5. Method of acquisition:
    Open-market repurchase through a trust bank
    (Reference)
    1. Details of the resolution at the Board of Directors’ meeting held on January 30, 2025
    (1) Class of shares to be acquired:
    Shares of common stock
    (2) Total number of shares to be acquired:
    Up to 28.5 million shares
    (equivalent to 1.80% of the total number of shares outstanding excluding treasury shares)
    (3) Total acquisition cost of shares to be acquired:
    Up to JPY 100 billion
    (4) Schedule of acquisition:
    From February 17, 2025 to May 31, 2025
    (5) Method of acquisition:
    Open-market repurchase through a trust bank
    2. Accumulated company’s own shares acquired through March 31, 2025, pursuant to the above Board resolution
    (1) Number of shares acquired:
    11,543,600 shares
    (2) Acquisition cost of shares acquired:
    JPY 49,977,908,700













    About Takeda Pharmaceutical Company Limited
    Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.
    Contacts    
    Investor Relations
    Christopher O’Reilly
    [email protected]
    +81 (0) 3-3278-2543
    Media Relations
    Brendan Jennings
    [email protected]
    +81 (0) 80-2705-8259
    (Outside Japan business hours)
    [email protected]


    Important Notice
    For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this press release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
    The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.


    Forward-Looking Statements
    This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects”, “forecasts”, “outlook” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

    ###


    Get the next $TAK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TAK

    DatePrice TargetRatingAnalyst
    4/2/2025Equal-Weight → Overweight
    Morgan Stanley
    3/16/2023$20.00Neutral → Buy
    BofA Securities
    7/19/2022$21.00 → $24.00Market Perform → Outperform
    Cowen
    10/7/2021Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $TAK
    SEC Filings

    See more
    • SEC Form 6-K filed by Takeda Pharmaceutical Company Limited

      6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)

      6/12/25 6:04:31 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Takeda Pharmaceutical Company Limited

      6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)

      6/10/25 6:08:34 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Takeda Pharmaceutical Company Limited

      6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)

      6/6/25 6:08:26 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TAK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Takeda Pharma upgraded by Morgan Stanley

      Morgan Stanley upgraded Takeda Pharma from Equal-Weight to Overweight

      4/2/25 8:46:19 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Takeda Pharma upgraded by BofA Securities with a new price target

      BofA Securities upgraded Takeda Pharma from Neutral to Buy and set a new price target of $20.00

      3/16/23 7:24:52 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Takeda Pharma upgraded by Cowen with a new price target

      Cowen upgraded Takeda Pharma from Market Perform to Outperform and set a new price target of $24.00 from $21.00 previously

      7/19/22 7:32:25 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TAK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Takeda Announces New Assignments of Directors

      Takeda (TYO:4502, NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting, following the 149th Annual Meeting of Shareholders, held in Osaka today. Takeda's Board of Directors has 11 members serving as external directors out of a total of 14 members, helping to ensure transparency and objectivity. An external director will continue to chair the Board of Directors. The Audit and Supervisory Committee, the Nomination Committee and the Compensation Committee will be composed solely of external directors including their chairs. Takeda highly values strong, independent governance and its Board of Directors helps to ensure that all decisions and acti

      6/25/25 3:07:00 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD

      - Approval Based on Positive Results from the Phase 3 HD21 Trial for Stage IIb with Risk Factors/III/IV Hodgkin Lymphoma - ADCETRIS-based Combination Demonstrated Superior Safety Profile and Efficacy Compared to eBEACOPP, a Standard of Care Regimen in Europe - Second Approval in Frontline Hodgkin Lymphoma Broadens ADCETRIS' Therapeutic Reach, Adding to Six Previously Approved, Distinct Indications for ADCETRIS in the European Union Takeda ((TAK) today announced that the European Commission (EC) approved ADCETRIS® (brentuximab vedotin) in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone (ECADD) – a chemotherapy regimen – in adult patients with ne

      6/3/25 10:12:00 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

      Rusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups, significantly reducing phlebotomy eligibility compared to placebo plus current standard of care, which was the primary endpoint All key secondary endpoints met with statistical significance, including a nearly three-fold reduction in the proportion of patients requiring phlebotomy and a four-fold improvement in hematocrit control in rusfertide arm compared to placebo arm, as well as improvements in patient-reported outcomes No serious adverse events considered related to rusfertide were reported Rusfertide has received Orphan Drug designation and Fast Track desig

      6/1/25 8:00:00 AM ET
      $PTGX
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TAK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3: New insider Takeda Pharmaceutical Co Ltd claimed ownership of 840,500 shares (Amendment)

      3/A - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Reporting)

      5/9/22 6:10:39 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3: New insider Takeda Pharmaceutical Co Ltd claimed ownership of 500,000 shares

      3 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Reporting)

      4/29/22 6:02:17 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Takeda Pharmaceutical Co Ltd

      3 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Reporting)

      10/21/21 8:40:37 PM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TAK
    Financials

    Live finance-specific insights

    See more
    • Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

      Rusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups, significantly reducing phlebotomy eligibility compared to placebo plus current standard of care, which was the primary endpoint All key secondary endpoints met with statistical significance, including a nearly three-fold reduction in the proportion of patients requiring phlebotomy and a four-fold improvement in hematocrit control in rusfertide arm compared to placebo arm, as well as improvements in patient-reported outcomes No serious adverse events considered related to rusfertide were reported Rusfertide has received Orphan Drug designation and Fast Track desig

      6/1/25 8:00:00 AM ET
      $PTGX
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress

      Core Revenue Growth of 7.4% at Actual Exchange Rates (AER), + 2.8% at Constant Exchange Rate (CER) in FY2024 Core Operating Profit Growth of 4.9% at CER with Efficiency Program Driving Cost Savings Up to Six New Molecular Entities in Phase 3 Development in FY2025 with Three Phase 3 Data Readouts Recently Completed or Anticipated FY2025 Outlook for Broadly Flat Revenue and Core Profit Reflecting Product Momentum and Increasing Investment in New Launch Preparation Proposed Dividend Increase from JPY 196 to JPY 200 Takeda ((4502, NYSE:TAK) today announced financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & Launch Products o

      5/8/25 2:36:00 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

      − Study met the primary endpoint, with a significantly higher proportion of clinical responders on rusfertide compared to placebo − All four key secondary endpoints were met, including EU primary endpoint and patient-reported outcomes − Rusfertide was generally well tolerated; no new safety findings were observed in the study Protagonist Therapeutics, Inc. ("Protagonist") ((PTGX) and Takeda ((TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. The study met its primary endpoint and all fou

      3/3/25 6:45:00 AM ET
      $PTGX
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care